In our exclusive collection of white papers, interviews and articles, pharma and life sciences experts discuss major developments in modern drug development.
Read about the potential of personalized medicine, immunotherapeutics in cancer treatment, the power of in silico profiling and big data, efforts to overcome antibiotic resistance and more!
Why is the World Health Organization concerned about a post-antibiotic era in which common infections can kill? What are the difficulties of designing antibacterial drugs? This exclusive article examines five antibiotic discovery programs to shed light on the challenges and possible solutions.
Since the early 1990s, R&D expenditure by U.S. pharmaceutical companies has grown exponentially, but not because more drugs are being produced and approved.
The vision for precision medicine is that it will offer improved treatments for patients, while also optimizing the drug development process as a whole.
Precision medicines display high efficacies against their target groups, but they still face the same problems as other drugs: high attrition rates during development, acquired resistance after launch and so on.